... This study aimed to clarify the mechanism of resistance to alectinib in LMC and seek a novel therapeutic strategy... Our findings may provide rationale for clinical trials to investigate the effects of novel therapies dual-targeting ALK and EGFR in ALK-rearranged NSCLC with alectinib-resistant LMC. READ ARTICLE
Journal of Thoracic Oncology DOI:10.1016/j.jtho.2019.12.076
Authors: S. Yano, S. Arai, K. Fukuda, S. Takeuchi